Keros Therapeutics Inc
Follow $KROS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $KROS by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredsnapshot unavailable for KROS. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is KROS moving today?
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
KROS overview
Related filings and maps
Congress activity in KROS
No receipt-qualified filings found.
KROS contract awards, year to date.
Public federal awards linked to this ticker.
KROS lobbying filings, year to date.
Registered lobbying filings matched to Keros Therapeutics Inc.